Veterinary Vaccine Adjuvants Market

Executive Summary

Veterinary Vaccine Adjuvants Market was valued at US $12.93 billion in 2021 and is projected to grow at 9.60% CAGR over the forecast period to reach US $22.42 billion by 2027. Veterinary Vaccine Adjuvants Market represented US $2.17 billion opportunity over 2019-2021 and estimated to create US $9.49 billion opportunity in 2027 over 2021.

Veterinary Vaccine Adjuvants from Consainsights analyses the Veterinary Vaccine Adjuvants Market in the Life Sciences industry over the forecast period to 2027.

Veterinary Vaccine Adjuvants research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Veterinary Vaccine Adjuvants segmentation includes Type, Route of Administration, Animal Type and Geography.

Based on the Type, the Veterinary Vaccine Adjuvants analysis covers Alum and Calcium Salts, Oil Emulsion Adjuvants, Liposomes and Archaeosomes, Nanoparticles and Microparticles, Other Types.

In Type segment, Alum and Calcium Salts segment has highest cagr growth of 8.49%.

Based on the Route of Administration, the Veterinary Vaccine Adjuvants analysis covers Oral, Subcutaneous, Intramuscular, Other Routes of Administration.

In Route of Administration segment, Oral segment has highest cagr growth of 8.49%.

Based on the Animal Type, the Veterinary Vaccine Adjuvants analysis covers Livestock, Companion Animal.

In Animal Type segment, Livestock segment has highest cagr growth of 8.49%.

Based on the region, the Veterinary Vaccine Adjuvants analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Bioveta AS, Brenntag Biosector AS, Novavax, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, Zoetis and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Alum and Calcium Salts segment has the highest revenue of US $5.73 billion and is expected to grow at CAGR of 8.49% by 2027 Alum and Calcium Salts segment has highest cagr growth of 8.49%.

Alum and Calcium Salts

Alum and Calcium Salts segment was valued at US $4.77 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $9.93 billion by 2027. Alum and Calcium Salts segment represented US $0.96 billion opportunity over 2019-2021 and estimated to create US $4.20 billion opportunity in 2027 over 2021.

Oil Emulsion Adjuvants

Oil Emulsion Adjuvants segment was valued at US $2.74 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $5.71 billion by 2027. Oil Emulsion Adjuvants segment represented US $0.55 billion opportunity over 2019-2021 and estimated to create US $2.42 billion opportunity in 2027 over 2021.

Liposomes and Archaeosomes

Liposomes and Archaeosomes segment was valued at US $1.96 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $4.09 billion by 2027. Liposomes and Archaeosomes segment represented US $0.40 billion opportunity over 2019-2021 and estimated to create US $1.73 billion opportunity in 2027 over 2021.

Nanoparticles and Microparticles

Nanoparticles and Microparticles segment was valued at US $0.67 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $1.39 billion by 2027. Nanoparticles and Microparticles segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.59 billion opportunity in 2027 over 2021.

Other Types

Other Types segment was valued at US $0.62 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $1.30 billion by 2027. Other Types segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.55 billion opportunity in 2027 over 2021.

Route of Administration

Introduction

In 2021, Oral segment has the highest revenue of US $6.14 billion and is expected to grow at CAGR of 8.49% by 2027 Oral segment has highest cagr growth of 8.49%.

Oral

Oral segment was valued at US $5.11 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $10.64 billion by 2027. Oral segment represented US $1.03 billion opportunity over 2019-2021 and estimated to create US $4.50 billion opportunity in 2027 over 2021.

Subcutaneous

Subcutaneous segment was valued at US $2.87 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $5.97 billion by 2027. Subcutaneous segment represented US $0.58 billion opportunity over 2019-2021 and estimated to create US $2.53 billion opportunity in 2027 over 2021.

Intramuscular

Intramuscular segment was valued at US $2.05 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $4.27 billion by 2027. Intramuscular segment represented US $0.41 billion opportunity over 2019-2021 and estimated to create US $1.81 billion opportunity in 2027 over 2021.

Other Routes of Administration

Other Routes of Administration segment was valued at US $0.74 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $1.54 billion by 2027. Other Routes of Administration segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.65 billion opportunity in 2027 over 2021.

Animal Type

Introduction

In 2021, Livestock segment has the highest revenue of US $7.25 billion and is expected to grow at CAGR of 8.49% by 2027 Livestock segment has highest cagr growth of 8.49%.

Livestock

Livestock segment was valued at US $6.04 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $12.57 billion by 2027. Livestock segment represented US $1.21 billion opportunity over 2019-2021 and estimated to create US $5.32 billion opportunity in 2027 over 2021.

Companion Animal

Companion Animal segment was valued at US $4.73 billion in 2019 and is projected to grow at 8.49% CAGR over the forecast period to reach US $9.85 billion by 2027. Companion Animal segment represented US $0.95 billion opportunity over 2019-2021 and estimated to create US $4.17 billion opportunity in 2027 over 2021.